Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer

Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.

(2017) Y. Y. Janjigian et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab

(2011) Toni M. Brand et al.   CANCER BIOLOGY & THERAPY

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

(2011) Y. Y. Janjigian et al.   CLINICAL CANCER RESEARCH

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

(2011) J. E. Chaft et al.   CLINICAL CANCER RESEARCH

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

(2008) J. Bean et al.   CLINICAL CANCER RESEARCH

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

(2008) H.-P. Kim et al.   MOLECULAR CANCER THERAPEUTICS